NCT03692442View on ClinicalTrials.gov

Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

UnknownOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

March 31, 2019

Conditions
Lung Cancer Non-small Cell Stage IV
Trial Locations (1)

510120

RECRUITING

Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Sponsors
All Listed Sponsors
collaborator

GeneCast Biotechnology Co., Ltd.

INDUSTRY

lead

Guangzhou Institute of Respiratory Disease

OTHER

NCT03692442 - Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform | Biotech Hunter | Biotech Hunter